All In Biotech

Drug Trial Radar · NCT07455734

Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

A Phase I/IIa, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 533 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

533

Planned (sponsor's estimate)

Start

Mar 30, 2026

Primary completion

Oct 2030

Study completion Oct 2030

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.; Biotheus (Hengqin) Co., Ltd.
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is the first time the drug BNT3214 (also referred to as PM8102) will be tested in people. It is designed to find out if the drug is safe and how well it works for adults with advanced solid tumors. The study will have three parts. The first two parts (Parts A and B) will focus on testing different amounts of BNT3214 to figure out the best and safest dose. The third part (Part C) will test selected doses of BNT3214 in multiple types of cancer.

Conditions

  • Advanced Solid Tumor Cancer

Interventions

  • BNT3214Drug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All parts - Number and percentage of participants with treatment emergent adverse events (TEAEs)Time frame: From the time of initiation of the first dose of BNT3214 until 90 days after the last dose of BNT3214
  2. All parts - Number and percentage of participants with dose interruptions, reductions, and discontinuation of BNT3214 due to TEAEsTime frame: Up to 24 months
  3. Parts A and B only - Number and percentage of participants with dose limiting toxicities (DLTs)Time frame: From first dose up to 28 days
  4. Part C only - Objective response rate (ORR)Time frame: Up to 30 months

Locations

16 sites in 4 countries. Site status is shown where the registry gives one.

  • Monash Medical Centre Clayton

    Clayton, Australia · Recruiting

  • Austin Health

    Heidelberg Heights, Australia · Not yet recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Not yet recruiting

  • Scientia Clinical Research Ltd

    Randwick, Australia · Not yet recruiting

  • Epworth HealthCare

    Richmond, Australia · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Recruiting

  • Nanfang Hospital of Southern Medical University

    Guangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Not yet recruiting

  • Shanghai East Hospital

    Shanghai, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam, South Korea · Not yet recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Not yet recruiting

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea · Not yet recruiting

  • Asan Medical Center

    Seoul, South Korea · Not yet recruiting

  • China Medical University Hospital

    Taichung, Taiwan · Not yet recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.